New hope for kidney disease: drug aims to slow damage in IgA nephropathy
NCT ID NCT04716231
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This phase 3 study tests a drug called atacicept in 376 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if atacicept can reduce protein in the urine and slow the decline in kidney function compared to a placebo. Participants must have a confirmed diagnosis and meet specific kidney function criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ORIGIN 3 Global Site Contact Information
Brisbane, California, 94005, United States
Conditions
Explore the condition pages connected to this study.